Igor Bilinsky - Net Worth and Insider Trading
Igor Bilinsky Net Worth
The estimated net worth of Igor Bilinsky is at least $46 dollars as of 2024-12-28. Igor Bilinsky is the Sr VP, Corporate Development of Fresh Tracks Therapeutics Inc and owns about 62 shares of Fresh Tracks Therapeutics Inc (FRTX) stock worth over $46. Details can be seen in Igor Bilinsky's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Igor Bilinsky has not made any transactions after 2015-07-13 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Igor Bilinsky
Igor Bilinsky Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Igor Bilinsky owns 5 companies in total, including Oncternal Therapeutics Inc (ONCT) , Armata Pharmaceuticals Inc (ARMP) , and Ignyta Inc (RXDX) among others .
Click here to see the complete history of Igor Bilinsky’s form 4 insider trades.
Insider Ownership Summary of Igor Bilinsky
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ONCT | Oncternal Therapeutics Inc | 2019-09-09 | Chief Business Officer |
| ARMP | Armata Pharmaceuticals Inc | 2017-01-30 | Chief Operating Officer |
| RXDX | Ignyta Inc | 2016-01-07 | GM & Immuno-Oncology/SVP Sp Ops |
 | | 2015-07-13 | Senior VP & Corporate Dev't |
| | 2021-03-15 | Chief Operating Officer |
Igor Bilinsky Latest Holdings Summary
Igor Bilinsky currently owns a total of 1 stock. Igor Bilinsky owns 62 shares of Fresh Tracks Therapeutics Inc (FRTX) as of July 13, 2015, with a value of $46.
Latest Holdings of Igor Bilinsky
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| FRTX | Fresh Tracks Therapeutics Inc | 2015-07-13 | 62 | 0.74 | 46 |
Holding Weightings of Igor Bilinsky
Igor Bilinsky Form 4 Trading Tracker
According to the SEC Form 4 filings, Igor Bilinsky has made a total of 0 transactions in Fresh Tracks Therapeutics Inc (FRTX) over the past 5 years. The most-recent trade in Fresh Tracks Therapeutics Inc is the sale of 0 shares on July 13, 2015, which brought Igor Bilinsky around $881.
Insider Trading History of Igor Bilinsky
- 1
Igor Bilinsky Trading Performance
Igor Bilinsky Ownership Network
Igor Bilinsky Owned Company Details
What does Oncternal Therapeutics Inc do?
Who are the key executives at Oncternal Therapeutics Inc?
Igor Bilinsky is the Chief Business Officer of Oncternal Therapeutics Inc. Other key executives at Oncternal Therapeutics Inc include director & Executive Chairman Robert James Wills , Chief Scientific Officer Gunnar F. Kaufmann , and Chief Medical Officer Salim Yazji .
Oncternal Therapeutics Inc (ONCT) Insider Trades Summary
Over the past 18 months, Igor Bilinsky made no insider transaction in Oncternal Therapeutics Inc (ONCT). Other recent insider transactions involving Oncternal Therapeutics Inc (ONCT) include a net purchase of 9,020 shares made by Robert James Wills , and a net purchase of 980 shares made by David F Hale .
In summary, during the past 3 months, insiders sold 0 shares of Oncternal Therapeutics Inc (ONCT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 980 shares of Oncternal Therapeutics Inc (ONCT) were sold and 10,980 shares were bought by its insiders, resulting in a net purchase of 10,000 shares.
Oncternal Therapeutics Inc (ONCT)'s detailed insider trading history can be found in Insider Trading Tracker table.
Oncternal Therapeutics Inc Insider Transactions
Igor Bilinsky Mailing Address
Above is the net worth, insider trading, and ownership report for Igor Bilinsky. You might contact Igor Bilinsky via mailing address: C/o Vical Incorporated, 10390 Pacific Center Court, San Diego Ca 92121.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
